This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

24/7 Access
Digital & In-Person

Marie Lindholm, PhD
VP, Head of Technology Innovation at Silence Therapeutics


As head of Molecular Design at Silence Therapeutics, Marie is leading a skilled team focusing on fine-tuning design of GalNAc-conjugated siRNA and exploring extra-hepatic siRNA targeting.Marie got solid academic experience as a cardiovascular researcher in Sweden, UK, and US before stepping into the world of oligonucleotide therapeutics, starting with LNA oligonucleotide research at Santaris Pharma.  When Santaris was acquired by Roche Marie was appointed Expert Scientist in Discovery Technology and Head of Targeted Delivery of oligonucleotide conjugates. Marie has authored >60 patents and peer-reviewed scientific publications, many in the fields of oligonucleotide drug design, safety, and function.

Agenda Sessions

  • A Toolbox for Optimizing Therapeutic GalNAc-conjugated siRNAs

    On Demand - Premium Only
  • Development of a Toolbox for Optimizing Therapeutic siRNA Conjugates

    On Demand - Premium Only